Introduction
Immune cells including macrophages and lymphocytes present at the bone remodeling site may regulate bone resorption (reviewed by Vaes [1] ). For example, interleukin 1 (IL-1) is the major osteoclast-activating cytokine produced by normal activated peripheral blood leukocytes (2) . Tumor necrosis factor-1. Abbreviations used in this paper: EMEM, Eagle's modified MEM; HBC, human bone cell(s); NK, natural killer (cell); TBS, Tris-buffered saline; TNF, tumor necrosis factor. alpha (TNFa)' produced by macrophages and the T lymphocyte-cytokine tumor necrosis factor-beta (TNFJ3) also have bone-resorbing activity in vitro (3) . These cytokines may stimulate osteoclast precursors (4) . In addition, osteoblasts are stimulated by IL-1, TNFa, and TNF/3 to release factors or mediate direct cell-cell membrane interactions activating osteoclastic bone resorption in vitro (5, 6) . By contrast, interferon-gamma (IFNy), released by activated T lymphocytes, inhibits immune cytokine (IL-1, TNFa, and TNFJ)-stimulated bone resorption in vitro (7) . These findings suggest that activated immune cells could be involved in bone resorption by release ofcytokines regulating the osteoclast lineage directly and/or through osteoblasts.
Factors that might direct immune cell activation at the remodeling site are unknown. An immune response, however, involves T lymphocyte recognition of antigen displayed on the surface of antigen-presenting cells (APC) in the context of a HLA class II molecule (for a review see Royer and Reinherz [8] ). As a consequence of this HLA class I-dependent T cell activation, a number of proteins are synthesized, including osteotropic cytokines (9) . Thus, presence ofHLA class Il-positive cells at the bone remodeling site may be essential for immune cell activation and local release of osteoclast-regulating cytokines.
We examined the expression of HLA class II determinants (DR and DQ) on human osteoblast-like bone cells (HBC) derived from normal trabecular bone surfaces in vitro. Moreover, regulation of HBC HLA class II expression by osteotropic factors were studied, including 1,25(OH)2D3, parathyroid hormone (PTH), calcitonin, purified human IL-1, and recombinant human IFNy (rIFNy, a known inducer ofclass II major histocompatibility complex molecules in a variety of immune and nonimmune cells [10] Table  I ). None of the patients showed signs of bone or joint disease or immune disorders.
Bone preparation and cell culture. Human trabecular bone sections were isolated and dissected into 0.3-0.5-cm fragments as described (11) . The fragments were washed vigorously in phosphate-buffered saline (PBS, pH 7.4) to remove marrow, seeded onto 9-cm plastic culture dishes (Falcon Labware, Oxford, UK) and cultured in Eagle's modified minimum essential medium (EMEM) containing 10 mM Hepes buffer, 10% fetal calf serum (FCS; heat-inactivated), 2 mM L-glutamine, 50 Ag/ml ascorbate, 50 U/ml penicillin, and 150 4g/ml streptomycin. All cell culture products were from Gibco Laboratories (Paisley, Scotland) and chemicals from Sigma Chemical Co. (Poole, Dorset, UK) unless otherwise stated. Cultures were kept at 37°C in a Table I. Percentages ofHLA-DR-and HLA-DQ-positive HBCfrom 10 Representative Donors   DR' cells   HLA-DR  12  DAKO-HLA-DR  DQ+ cells Leu-l0   Donor   Length of culture  FACS  IP  FACS  IP  FACS   IP  FACS   IP   wk   %   1  5  26  23  23  23  ND  ND  9  8  2  11  14  15  12  13  ND  ND  5  5  3   7  10  ND  13  ND  ND  ND  7  ND  4   21*   24  24  22  21  26  25  15  13  5  14  30  28  25  29  30  29  9  9  6 25 (Table II) . None of the cells showed phagocytic activity as determined by latex ingestion. A faint staining for nonspecific esterase in all HBC (previously described in a similar cell system [15] ) contrasted with the bright membrane Fig. 2 . Although 0-9% DR' cells were present immediately after sort in the low-density DR fraction, these cells diminished after replating (after 48 h of culture 0-2% DR' cells remained in the DR-fraction). Neither conditioned medium from the presort HBC or postsort DR' fraction added to the DR-fraction nor conditioned medium from the presort HBC or postsort DR- idly disappeared within 48 h as detected by immunoperoxidase staining, the percentage of DR' cells, having remained stable for at least 1 wk, gradually diminished in the high-density postsort culture after 2-4 wk (a range of 5-40% reduction in numbers of DR' cells). In addition, the high-density populations showed signs of increasing cell death after 4-6 wk in culture. By contrast, the low-density population remained stable in long-term culture without reappearance of DR' cells when reexamined after 2-4 wk. Nevertheless, reappearance of DR-expressing HBC in these populations at a later stage has not been determined.
A total of four experiments on osteocalcin production by different pre-and postsort HBC populations were undertaken. Fig. 3 illustrates one representative experiment. Osteocalcin was produced by 1,25(OH)2D3-stimulated unseparated HBC as previously reported (1 1). Both DR' and DR-sorted HBC produced osteocalcin in a dose-dependent manner when stimulated by 1,25(OH)2D3 48 h and similarly 1 wk after cell separation. In the DR' populations HLA-DR and osteocalcin were coexpressed since they were both present in 2 95% of the cells (data not shown).
rIFN-y and 1,25(OH)2D3 stimulate HBC HLA class II expression, whereas IL-], PTH, and calcitonin have no effect alone or with rIFN-y. To test the influence of osteotropic hormonal factors on HBC HLA-DR and DQ expression six experiments on different HBC cultures were undertaken. In Table III results (Table III) (20) has not been excluded. The separated high-and low-density DR-expressing populations did not revert back to the original distribution after 4 wk of postsort culture. On the contrary, the DR' subset rapidly disappeared from the low-density fraction and after 2 wks were reduced in the high-density fraction. Possibly, the DR' subset may be more fragile than their DR-counterpart and thus damaged selectively during the FACS procedures. Alternatively, the DR' phenotype may depend upon factors expressed within the unseparated population only.
The observation that IFNy stimulates HBC HLA-DR expression is in accordance with data on other connective tissue cells including human dermal fibroblasts (18) , human synovial fibroblasts (21) , and human chondrocytes (19) . Although IFNy induces HLA-DQ in certain cells including monocytes (22) , this cytokine has been reported to induce only low levels or no HLA-DQ determinants on connective tissue cells such as synovial fibroblasts (23), chondrocytes (19) , and, as in this study, HBC.
In contrast with two other major bone resorbing factors, PTH (10-9 to 10-7 M) and IL-l (5-50 U/ml), 1,25(OH)2D3 (10-9 to 10-7 M) enhanced IFN'y-stimulated HBC HLA-DR expression and at high supraphysiological levels (lO-' M) stimulated DR expression by itself. Similar findings have been reported regarding the Ia-negative murine myelomonocytic cell line WEHI-3 (24) . In this study 1,25(OH)2D3 (1010 to I0-8 M) was found to enhance IFNy-induced Ia expression. By contrast, using a HLA class II-positive melanoma cell line, Carrington et al. (25) found a dose-dependent inhibition of DRa mRNA by 1,25(OH)2D3 (10-12 to 10-8 M). In other class II-positive cell lines, however, class II molecules were not altered by 1,25(OH)2D3 (26) . Factors affecting class II expression in opposite directions, released during 1,25(OH)2D3 stimulation, might explain the differences between the cell lines. Thus, 1,25(OH)2D3 has been reported to stimulate production of IFN'y by T lymphocytes in vitro (26) . To test the possibilities that 1,25(OH)2D3 (a) stimulates factors, such as IFNy, which induce class II expression in the HBC cultures and/or (b) enhances the responsiveness of HBC to IFNy by altering HBC proliferation, further studies are needed. Calcitonin, which inhibits the bone-resorbing activity of osteoclasts (27) and also may affect osteoblasts (28) , did not alter HBC DR expression (I0-9 to 10-8 M) suggesting that a change in HBC DR levels is not involved in calcitonin-mediated osteoclast inhibition.
We suggest that HLA class II-positive bone surface cells of the osteoblast lineage may play a role in local T lymphocyte activation including release of osteoclast-activating T lymphocyte-derived cytokines. Thus, studies are in progress on the abilities of HBC to stimulate in mixed lymphocyte reaction (MLR) and to present antigen (29) . Since the presence of IL-1 may be important for these activities the recent finding of constitutive IL-I production by HBC (30) is of interest. Enhancement of HBC HLA class II expression by IFNy and 1,25(OH)2D3 could be involved in the osteotropic activity of these factors.
